methylphenidate has been researched along with Adverse Drug Event in 22 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17." | 5.13 | Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. ( Bukstein, OG; Daviss, WB; Harris, P; McDERMOTT, MP; Palumbo, D; Patel, NC; Pelham, WE; Robb, AS; Sallee, FR, 2008) |
| " Among 433 randomized patients, adverse events (AEs) were documented and analyzed on an "as received" basis during week 0-52." | 2.94 | Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study. ( Abdel-Hamid, M; Alm, B; Berger, M; Borel, P; Colla, M; Graf, E; Heßmann, P; Huss, M; Jacob, C; Jans, T; Kis, B; Lücke, C; Matthies, S; Müller, HHO; Philipsen, A; Retz, W; Rösler, M; Sobanski, E; van Elst, LT, 2020) |
| " Trials of amphetamines, atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil with a placebo arm and reporting data on headache as an adverse event, were included." | 2.82 | Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. ( Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS, 2022) |
| "The purpose of this study was to investigate whether the availability of both dextroamphetamine and methylphenidate provides an opportunity to minimize adverse events in a pediatric attention-deficit/hyperactivity disorder (ADHD) stimulant trial." | 2.79 | Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. ( Aabech, HS; Ramtvedt, BE; Sundet, K, 2014) |
| "The side effect profile as assessed by the SERS was similar to that of previous studies with insomnia, decreased appetite, and headaches showing significant treatment effects (p < 0." | 2.76 | Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. ( Bhat, V; Grizenko, N; Joober, R; Lee, J; Polotskaia, A; Sengupta, S, 2011) |
| " Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications." | 2.55 | An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. ( Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017) |
| "Methylphenidate is an effective first-line treatment for attention-deficit/hyperactivity disorder (ADHD)." | 1.91 | The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis. ( Kim, E; Lee, H; Oh, S; Park, S; Purja, S; Shin, H; Yuniar, CT, 2023) |
| "Modafinil was associated with DAAD in the total dataset (ROR, 2." | 1.46 | Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. ( Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, C; Zeiss, R, 2017) |
| " The risk of adverse drug-drug interaction(s) is present when metabolic inhibitors are combined with known or suspected substrates of a given enzyme." | 1.36 | Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. ( Appel, DI; Markowitz, JS; Peterson, YK; Wang, Z; Zhu, HJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 8 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Dubrall, D | 1 |
| Leitzen, S | 1 |
| Toni, I | 1 |
| Stingl, J | 1 |
| Schulz, M | 1 |
| Schmid, M | 1 |
| Neubert, A | 1 |
| Sachs, B | 1 |
| Pan, PY | 1 |
| Jonsson, U | 1 |
| Şahpazoğlu Çakmak, SS | 1 |
| Häge, A | 1 |
| Hohmann, S | 1 |
| Nobel Norrman, H | 1 |
| Buitelaar, JK | 1 |
| Banaschewski, T | 1 |
| Cortese, S | 2 |
| Coghill, D | 1 |
| Bölte, S | 1 |
| Groom, MJ | 1 |
| Akhlaque, E | 1 |
| Shin, H | 1 |
| Yuniar, CT | 1 |
| Oh, S | 1 |
| Purja, S | 1 |
| Park, S | 1 |
| Lee, H | 1 |
| Kim, E | 1 |
| Kis, B | 1 |
| Lücke, C | 1 |
| Abdel-Hamid, M | 1 |
| Heßmann, P | 1 |
| Graf, E | 1 |
| Berger, M | 1 |
| Matthies, S | 1 |
| Borel, P | 1 |
| Sobanski, E | 1 |
| Alm, B | 1 |
| Rösler, M | 1 |
| Retz, W | 1 |
| Jacob, C | 1 |
| Colla, M | 1 |
| Huss, M | 1 |
| Jans, T | 1 |
| van Elst, LT | 1 |
| Müller, HHO | 1 |
| Philipsen, A | 1 |
| Elliott, J | 1 |
| Johnston, A | 1 |
| Husereau, D | 1 |
| Kelly, SE | 1 |
| Eagles, C | 1 |
| Charach, A | 1 |
| Hsieh, SC | 1 |
| Bai, Z | 1 |
| Hossain, A | 1 |
| Skidmore, B | 1 |
| Tsakonas, E | 1 |
| Chojecki, D | 1 |
| Mamdani, M | 1 |
| Wells, GA | 1 |
| Nourbakhsh, B | 1 |
| Revirajan, N | 1 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 1 |
| Svendsen, K | 1 |
| Halvorsen, KH | 1 |
| Vorren, S | 1 |
| Samdal, H | 1 |
| Garcia, B | 1 |
| Ramtvedt, BE | 1 |
| Aabech, HS | 1 |
| Sundet, K | 1 |
| Li, Y | 1 |
| Gao, J | 1 |
| He, S | 1 |
| Zhang, Y | 1 |
| Wang, Q | 1 |
| Gahr, M | 1 |
| Connemann, BJ | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Zeiss, R | 1 |
| Zhu, HJ | 1 |
| Appel, DI | 1 |
| Peterson, YK | 1 |
| Wang, Z | 1 |
| Markowitz, JS | 1 |
| Tobaiqy, M | 1 |
| Stewart, D | 1 |
| Helms, PJ | 1 |
| Bond, C | 1 |
| Lee, AJ | 1 |
| Bateman, N | 1 |
| McCaig, D | 1 |
| McLay, J | 1 |
| Lee, J | 1 |
| Grizenko, N | 1 |
| Bhat, V | 1 |
| Sengupta, S | 1 |
| Polotskaia, A | 1 |
| Joober, R | 1 |
| Kim, J | 1 |
| Kim, M | 1 |
| Ha, JH | 1 |
| Jang, J | 1 |
| Hwang, M | 1 |
| Lee, BK | 1 |
| Chung, MW | 1 |
| Yoo, TM | 1 |
| Kim, MJ | 1 |
| Olfson, M | 1 |
| Huang, C | 1 |
| Gerhard, T | 1 |
| Winterstein, AG | 1 |
| Crystal, S | 1 |
| Allison, PD | 1 |
| Marcus, SC | 1 |
| Duong, S | 1 |
| Chung, K | 1 |
| Wigal, SB | 1 |
| Humphreys, C | 1 |
| Garcia-Bournissen, F | 1 |
| Ito, S | 1 |
| Koren, G | 1 |
| Daviss, WB | 1 |
| Patel, NC | 1 |
| Robb, AS | 1 |
| McDERMOTT, MP | 1 |
| Bukstein, OG | 1 |
| Pelham, WE | 1 |
| Palumbo, D | 1 |
| Harris, P | 1 |
| Sallee, FR | 1 |
| Springer, NS | 1 |
| Fricke, NL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD[NCT01220440] | Phase 4 | 36 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
7 reviews available for methylphenidate and Adverse Drug Event
| Article | Year |
|---|---|
Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Sti | 2022 |
Current Pharmacological Treatments for ADHD.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central | 2022 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes | 2020 |
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidi | 2017 |
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2012 |
Exposure to attention deficit hyperactivity disorder medications during pregnancy.
Topics: Abnormalities, Drug-Induced; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivit | 2007 |
Nutrition and drug therapy for persons with developmental disabilities.
Topics: Anticonvulsants; Antidepressive Agents; Appetite; Dextroamphetamine; Drug-Related Side Effects and A | 1975 |
5 trials available for methylphenidate and Adverse Drug Event
| Article | Year |
|---|---|
Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dextroamphetam | 2014 |
Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous System Sti | 2011 |
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.
Topics: Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Bradycardia; Central Nervo | 2008 |
10 other studies available for methylphenidate and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
Topics: Adolescent; Atomoxetine Hydrochloride; Child; Child, Preschool; Drug Combinations; Drug-Related Side | 2021 |
Alice in Wonderland Syndrome as a potential side-effect in Attention Deficit Hyperactivity Disorder patients undergoing Methylphenidate treatment.
Topics: Alice in Wonderland Syndrome; Attention Deficit Disorder with Hyperactivity; Drug-Related Side Effec | 2023 |
The Adverse Effects and Nonmedical Use of Methylphenidate Before and After the Outbreak of COVID-19: Machine Learning Analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Central Nervous System Stimulants; COV | 2023 |
Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Central Nervous System Stimulants; Databases, | 2018 |
Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
Topics: Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Au | 2017 |
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Carboxyl | 2010 |
A pilot study to evaluate a community pharmacy-based monitoring system to identify adverse drug reactions associated with paediatric medicines use.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Atomoxetine Hydrochloride; Chi | 2010 |
Signal detection of methylphenidate by comparing a spontaneous reporting database with a claims database.
Topics: Adverse Drug Reaction Reporting Systems; Data Mining; Databases, Factual; Drug-Related Side Effects | 2011 |
Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Amphetamines; Angina Pectoris; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyp | 2012 |